Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated...
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...
The S&P 500 Index ($SPX ) (SPY ) on Monday closed down by -0.53%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down by -0.90%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.36%....
The S&P 500 Index ($SPX ) (SPY ) today is down by -0.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.29%. December E-mini...
The S&P 500 Index ($SPX ) (SPY ) today is down by -0.59%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.40%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.97%. December E-mini...
WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...
Initiated PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis Successfully completed drug-drug interaction...
WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...